|Dr. Stephen J. Farr Ph.D.||Co-Founder, CEO, Pres & Director||677.89k||N/A||58|
|Mr. Roger L. Hawley||Co-Founder & Director||N/A||N/A||64|
|Dr. Bradley S. Galer M.D.||Exec. VP & Chief Medical Officer||510.23k||N/A||55|
|Dr. Gail M. Farfel Ph.D.||Exec. VP & Chief Devel. Officer||477.06k||N/A||53|
|Ms. Ann D. Rhoads||Consultant||498.27k||N/A||52|
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Zogenix, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 9.